摘要
奥马珠单抗是第一个抗IgE人源化单克隆抗体，已作为重度哮喘患者的附加治疗药物写入GINA和我国的哮喘指南中。奥马珠单抗可减轻哮喘患者气道炎症和气道重塑，经大剂量吸入性糖皮质激素和长效口受体激动剂后仍未控制的成人和6岁以上儿童，附加该药治疗可以获得较好的临床疗效和安全性。奥马珠单抗已完成在我国的注册临床研究，其疗效和安全性与国外研究相仿。该药即将在我国上市，它将给重度哮喘患者提供新的治疗方式。
Omalizumab is the first humanized monoclonal antibody against IgE. It has been used as an additional therapeutic drug in GINA and Chinese asthma guideline for patients with severe asthma. Omalizumah can alleviate airway inflammation and airway remodeling. The uncontrolled severe asthma patients （adults and children over 6 or older） who are taking high doses inhaled corticosteroid and long acting beta agonist may achieve good clinical efficacy and safety from Omalizumab therapy. The registered clinical research of Omalizumab in China was completed, and the efficacy and safety results were similar to research results abroad. Omalizumab will be available in China soon, it will provide a new treatment to the severe asthma patients.
出处
《国际呼吸杂志》
2016年第13期998-1001,共4页
International Journal of Respiration
基金
国家自然科学基金面上项目（81470218）
上海市卫生局青年科研项目（2012Y119）
